Delphine Imbert

Delphine is Senior Vice President, CMC and Technical Operations at Chinook Therapeutics. Prior to Chinook, Delphine was Senior Vice President, Pharmaceutical Sciences at Dermira where she established Dermira’s fully virtual CMC, manufacturing, and supply chain capabilities enabling the successful development, approval, and launch of QBREXZA® (glycopyrronium) cloth in hyperhidrosis, as well as the progression of a portfolio of small molecules at all stages of development and the development of lebrikizumab up to Phase 3 until its acquisition in 2020 by Eli Lilly and Company. Prior to Dermira, Delphine served as Vice President, Pharmaceutical R&D at Anacor Pharmaceuticals, and held various leadership roles at ALZA Corporation (a Johnson & Johnson company) and Cellegy Pharmaceuticals. Delphine conducted her postdoctoral training at the University of California, San Francisco, holds a Ph.D. in Pharmaceutical Sciences from the University of Cincinnati, and a Master’s degree in Chemical Engineering and Chemistry from Chimie ParisTech, Paris, France.